Search the Community

Case Report: Multifactorial Pulmonary Hypertension in Systemic Sclerosis. We present a case of pulmonary arterial hypertension (PAH) in a patient with rapidly progressing symptoms to highlight the need for an early and thorough diagnostic workup. PubMed, Cureus. (Also see Pulmonary Hypertension Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Patients with scleroderma require 'annual screening' for pulmonary arterial hypertension. Every patient with systemic sclerosis should be screened for pulmonary arterial hypertension every year, as early recognition, referral and aggressive treatment are necessary to improve long–term outcomes, according to Virginia Steen, MD. Healio Rheumatology, 05/22/2019. (Also see Pulmonary Hypertension Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Use of red cell distribution width (RDW) in a population at high risk for pulmonary hypertension (PH). The ease of obtaining RDW as a biomarker may help detect incident PH at earlier stages among patients who are at high risk for development of PH. PubMed, Respir Med, 2019 Apr;150:131-135. (Also see Pulmonary Hypertension Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. 

Incidence of pulmonary hypertension (PH) and determining factors in patients with systemic sclerosis (SSc). It was possible to identify manifest PH in almost 25% of patients using prospective right heart catheterisation during follow-up. PubMed, Eur Respir J, 2018 Apr 4;51(4). (Also see Pulmonary Hypertension Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension (PAH). Plasma levels of PlGF, sVEGFR-1, TNF-α, and VEGF-D have potential in screening for SSc–associated PAH. Plasma sVEGFR-1 may be a biomarker of treatment response. PubMed, Scand J Rheumatol, 2018 Mar 12:1-6. (Also see Pulmonary Hypertension Diagnosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.